What is it about?
This paper showcases how Tolvaptan (only one proven medication to potentially slow cyst growth in patients with aggressive Autosomal Dominant Polycystic Kidney Disease: ADPKD) has been used in our Nurse-led ADPKD clinic in Queen Elizabeth Hospital Birmingham: QEHB).
Featured Image
Why is it important?
Somehow, the rate of tolvaptan use varies among hospitals despite robust evidence, probably due to the challenging side-effect (make you wee about 5-6L/day, compared to usual 1-2L/day) and frequent blood test requirement, necessitating a dedicated tolvaptan clinic. We showed the successful Nurse-led clinic in QE comparing the data before and after the initiation of tolvaptan.
Perspectives
I hope any nephrology departments where there are no dedicated tolvaptan clinics to be reassured to set-up such clinics, based on our results. The nurse-led tolvaptan clinic with sufficient supervision is not only safe and cost-effective but empowering.
Dr Yuki Heath
New Queen Elizabeth Hospital Birmingham
Read the Original
This page is a summary of: The real world experience of tolvaptan use in patients with autosomal dominant polycystic kidney disease, Journal of Kidney Care, November 2024, Mark Allen Group,
DOI: 10.12968/jokc.2024.9.6.276.
You can read the full text:
Contributors
The following have contributed to this page
